

Report from ESCMID Global 2025, Vienna – (12 April 2025)



RSV infections: diagnosis, surveillance and treatment in the advent of vaccines

Organised by the ISIRV Epidemiology Group and ESCMID Study Group for Respiratory Viruses (ESGREV) for ESCMID and the International Society for Influenza and other Respiratory Viruses (ISIRV)

For the third consecutive year, ISIRV and the ISIRV Epidemiology Group and the ESCMID Study Group for Respiratory Viruses (ESGREV) successfully joined forces to deliver a high-profile educational session at ESCMID Global. This ongoing collaboration between ESGREV and ISIRV continues to foster scientific exchange and visibility.

This year's session at ESCMID Global Saturday 12 April 2025 in Vienna, Austria consisted of a 2hr educational session titled 'RSV Infections: diagnosis, surveillance and treatment in the advent of vaccines'.

The session aimed to elucidate the status of RSV diagnostics, surveillance, and management in the advent of RSV vaccine introduction. The speakers looked at challenges in diagnostics, newest data on antiviral drug development versus symptomatic and supportive care, which treatment options (if any) to use, when to initiate, how long to treat, which age and risk groups to prioritise. The session explored the need to obtain vaccination histories and manage infections differently in patients who report having received monoclonals or vaccines. The session was accredited for CME and was designed to bring together leading voices in RSV research and clinical care to help update a broad European audience. For more information, please refer to the [ESCMID Global 2025 program](#)

Presentation(s)

Costs of RSV infection, compared to other respiratory viruses (Barbara RATH)

Virology and host interactions of RSV (Peter OPENSHAW)

RSV surveillance in the EU/EEA in the vaccine era (Eeva BROBERG)

RSV fusion inhibitors and monoclonals: current status and future developments (Louis BONT)

01. Viral infection & disease (incl COVID-19)

RSV infections: diagnosis, surveillance and treatment in the advent of vaccines

CLN DX VAX

CME

12 Apr 2025, 08:30 - 10:30

Hall 13

Remove from my agenda

Locate room

Educational Session

Overview

Organized by ESCMID Study Group for Respiratory Viruses (ESGREV), International Society for Influenza and other Respiratory Viruses (ISIRV)

Overview

Organized by ESCMID Study Group for Respiratory Viruses (ESGREV), International Society for Influenza and other Respiratory Viruses (ISIRV)

This educational session aims to elucidate the status of RSV diagnostics, surveillance, and management in the advent of RSV vaccine introduction. The speakers will look at challenges in diagnostics, newest data on antiviral drug development versus symptomatic and supportive care, which treatment options (if any) to use, when to initiate, how long to treat, which age and risk groups to prioritise. The session will explore the need to obtain vaccination histories and manage infections differently in patients who report having received monoclonals or vaccines.

Chairs



Monika REDLBERGER-FRITZ, Austria
Chair



Makeda SEMRET, Canada
Chair

Presentation(s)

Costs of RSV infection, compared to other respiratory viruses

08:30 - 08:50



Barbara RATH, France

Virology and host interactions of RSV

08:50 - 09:10



Peter OPENSHAW, United Kingdom

RSV surveillance in the EU/EEA in the vaccine era

09:10 - 09:30



Eeva BROBERG, Sweden

RSV fusion inhibitors and monoclonals: current status and future developments

09:30 - 09:50



Louis BONT, Netherlands

